Chordia Therapeutics (190A) Reports Earnings: Operating Loss of 662 Million Yen

Chordia Therapeutics (190A) has released its latest financial results, reporting an operating loss of 662 million yen, an ordinary loss of 632 million yen, and a net loss of 633 million yen. Basic earnings per share (EPS) stood at -8.95 yen.

From a balance sheet perspective, the company maintains a robust equity ratio of 91.8%, reflecting a strong financial foundation. Meanwhile, retained earnings were recorded at -0.63 billion yen, and cash and cash equivalents stood at 2.45 billion yen. As a drug-discovery biotech venture continuing its R&D investments, the market will likely focus on its future business progress and path toward profitability supported by its solid capital base and liquidity.